Vaccination in the EU, ENVI Committee, European Parliament 17 June 2015
Download as PPTX, PDF2 likes1,130 views
The document discusses vaccination programs in the EU, emphasizing their benefits and barriers, including the effectiveness of the measles, mumps, and rubella (MMR) vaccine. It identifies vaccine hesitancy, underserved populations, and vaccine availability as key challenges preventing the achievement of vaccination targets. The ECDC is working to strengthen vaccination programs through evidence-based communication, support for member states, and initiatives to address public health policies.
Vaccination in the EU, ENVI Committee, European Parliament 17 June 2015
- 1. ENVI Committee exchange of view Vaccination in the EU: benefits and barriers Prof Mike Catchpole, Chief Scientist European Centre for Disease Prevention and Control ENVI Committee 17 June 2015, European Parliament, Brussels
- 2. December 2004 October 2012 Why do EU Member States have vaccination programmes? To protect the health of Europeans
- 3. Finland - reported measles, mumps, and rubella through November, 2007, since 1915 for measles, 1943 for mumps, and 1957 for rubella* *Peltola et al Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme Lancet 2008; issue 8 vol 12; 796–803 Through MMR vaccination measles complications averted Hospitalisations: 1 per 5 cases Otitis media: 1 per 11 cases Pneumonia: 1 per 12 cases Encephalitis: 1 per 1,000 cases Subacute sclerosing panencephalitis: 1 per 100,000 Deaths: 1 per 1,000 to 5,000 cases mumps complications averted Hospitalisations: 1 per 25 cases Meningitis: 1 per 12 cases Bilateral orchitis: 1 per 30 cases Encephalitis: 1 per 300 cases Pancreatitis: 1 per 500 cases Hearing impairment: 1 per 300 to 1,000 cases rubella complications averted Congenital rubella syndrome: 1 per 400 cases Post-infectious encephalopathy: 1 per 500,000 cases
- 4. Vaccines used in EU are highly safe
- 6. Vaccination policy in Europe is not achieving its public health goals Example: elimination of measles in Europe by 2010, 2015, 2020 (?!) Source: TESSy data on measles cases reported 1 January – 30 April 2015; Measles vaccine coverage (two doses, 2012 – 2013)
- 7. EU citizens still die from vaccine preventable diseases! The threat continues
- 8. Why vaccination targets are not met (1): Vaccine hesitancy • Influenced by issues of confidence (level of trust in vaccine or provider), complacency (do not perceive need for vaccine) and convenience (access). • Hesitant citizens may: i) accept all vaccines but remain concerned; or ii) refuse or delay some vaccines; or iii) refuse all vaccines • Results of the ECDC study: – Main concern/ fear: vaccine safety – Hesitancy among healthcare professionals Vaccine safety concerns Incidence of disease Source: Rapid literature review on motivating hesitant population groups in Europe to vaccinate, ECDC, 2015 (under editing).
- 9. Why vaccination targets are not met (2): Under-served population groups Photo credits: www.vam.ac.uk/moc/images/image/36307-popup.html, by Eithne Nighingale http://www.flickr.com/photos/87563734@N00/ by Henri Weisen
- 10. Why vaccination targets are not met (3): Vaccine availability • Currently, almost one third of Member States have reported difficulties in procuring vaccines for the vaccination of infants against pertussis (whooping cough). • Three out of nine influenza vaccine producers in EU closed production in the last two years (Baxter, Crucell & Cantacuzzino).
- 11. Strengthening prevention and control: What ECDC is currently doing 2015 will aim at: Supporting in responding to the existing and upcoming Council Conclusions on immunisation Providing evidence-based communication tools for reaching hesitant groups Fostering exchange of knowledge to strengthen vaccination programmes - VENICE project Coordinating and supporting EU-wide VPD network Supporting Member States with country visits upon request ECDC works in a multi-disciplinary approach… …to support and strengthen prevention and control efforts on vaccine preventable diseases (VPDs) in the EU/EEA.
- 12. What more can be done at EU level? • Support for EU level projects on key issues such as: – vaccine hesitancy – under-served populations – immunity gaps etc. • EU action to further improve evidence-base for public health (national and EU level) decisions on vaccination policy – ECDC guidance – Robust vaccine monitoring data
Editor's Notes
- #3: Max, 18 year old, victim of Subacute Sclerosing Pan-Encephalitis in 2012. Max died in 2014 http://www.vaccinestoday.eu/vaccines/how-measles-can-change-a-life/
- #9: Vaccine hesitancy = a behaviour, influenced by a number of factors including issues of confidence [level of trust in vaccine or provider], complacency [do not perceive a need for a vaccine, do not value vaccine] and convenience [access]. - May accept all vaccines but remain concerned, may refuse or delay some vaccines or may refuse all vaccines Results of the ECDC study: Main concern/ fear: vaccine safety Hesitant vaccine providers and healthcare professionals ECDC’s next steps: a qualitative study under implementation publish all results in a comprehensive report design a communication guide
- #10: Photos: irregular migrants (top left), the Roma (right) and travelling communities (bottom left) Some population groups have limited or difficult access to preventative services due to: social exclusion; poverty; convenience ECDC implemented an action plan on measles and rubella, to contribute to the WHO targets on eliminating these One area of this plan was capacity building at the MS level; ECDC designed and implemented pilot projects targeting the under-served population groups, mainly Roma. These projects were aimed at equipping the healthcare professionals with communication tools to be used in their daily practice when addressing vaccination topics with parents and grandparents.